PfRH5 adjuvanted with Matrix-M (UOXF, UK)
This protein-in-adjuvant blood-stage vaccine comprises the highly conserved RH5 antigen.
This candidate vaccine developer is The Chancellor, the Masters and the Scholars of the University of Oxford, United Kingdom.
It recently became the first blood-stage candidate to demonstrate in vivo impact on P. falciparum parasite blood-stage growth in a CHMI trial in the UK (ClinicalTrials.gov Identifier: NCT02927145). Trials of RH5 vaccines are in progress in Tanzania (ClinicalTrials.gov Identifier: NCT03435874).